Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciencesMeet ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

Dr. Lubor Gaal joins MitoRx on a part-time basis, bringing over 25 years of global experience in business development, licensing, and strategic partnerships within the pharmaceutical and biotechnology ...

Looking for broad exposure to the Large Cap Blend segment of the US equity market? You should consider the SPDR Russell 1000 Low Volatility Focus ETF (ONEV), a passively managed exchange traded fund ...